The Utility of PSMA PET for a Patient with Metastatic Castrate-Resistant Prostate Cancer Case of the Month – Ephraim Parent
Story: https://www.urotoday.com/video-lectures/snmmi-case-of-the-month/video/3317-the-utility-of-psma-pet-for-a-patient-with-metastatic-castrate-resistant-prostate-cancer-case-of-the-month-ephraim-parent.html Ephraim Parent presents a case highlighting the utility of PSMA PET for a patient with metastatic castrate-resistant prostate cancer. The PSMA PET scan revealed discordant disease, with soft tissue predominantly FDG-avid and the osseous disease either matching hypermetabolic and PSMA-avid lesions or predominantly PSMA. Based on these findings, the patient was determined to […]
UBC ranked 22nd in the world for life sciences and medicine
Story: https://www.med.ubc.ca/news/ubc-ranked-22nd-in-the-world-for-life-sciences-and-medicine/?utm_source=newsletter&utm_medium=email&utm_campaign=thelink UBC is now ranked 22nd in the world for life sciences and medicine according to the latest QS World University Rankings. UBC is consistently among the top-tier life sciences and medical schools around the globe and this latest ranking represents the university’s highest placing ever, up two spots from 2022. Dr. Dermot Kelleher “These […]
UBC biotech spin-off raises $75M to bring cancer treatments to patients
Story: https://www.med.ubc.ca/news/ubc-biotech-spin-off-raises-75m-to-bring-cancer-treatments-to-patients/?utm_source=newsletter&utm_medium=email&utm_campaign=thelink With roots in UBC research, Alpha-9 Theranostics is developing cancer radiotherapies that target tumours while avoiding healthy tissues. Alpha-9 Theranostics, a UBC spin-off company founded by three university researchers, has raised $75 million to develop next-generation radiopharmaceuticals that promise to meaningfully improve treatment for people with cancer. Based on more than a decade […]
Dr. Ravi on the increased burden of the 177Lu-PSMA-617 shortage for newly referred patients
Story: https://www.urologytimes.com/view/dr-ravi-on-the-increased-burden-of-the-177lu-psma-617-shortage-for-newly-referred-patients “Where it’s feasible and where the patients are eligible, I and others are trying to use alternative therapies, which have probably a similar impact in terms of improving longevity of life for patients [with prostate cancer],” says Praful Ravi, MD, BChir, MRCP. In this interview, Praful Ravi, MD, BChir, MRCP, discusses the impact of the […]
PSMA-PET Improves Prostate Cancer Staging, Influences Decision-Making
Story: https://www.renalandurologynews.com/home/news/urology/prostate-cancer/psma-pet-improves-prostate-cancer-staging-influences-decision-making/ Prostate-specific membrane antigen positron emission tomography (PSMA-PET) should be performed only in patients with high-risk or unfavorable intermediate-risk prostate cancer staging, according to a recent review published in European Urology Oncology. Due to its suboptimal sensitivity for lymph node metastasis, it should not be used to avoid pelvic lymph node dissection during radical prostatectomy […]
Lutetium PSMA therapy: Target and Destroy Cancer Cells
Lutetium PSMA therapy is a treatment for cancer that uses a special type of radiation called lutetium-177 to target and destroy cancer cells. This therapy is used specifically for prostate cancer that has spread to other parts of the body and is called metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA) is a protein […]
World Theranostics Day
March 31 is World Theranostics Day. This day is all about raising awareness and celebrating the importance of using theranostics in medicine. Now, you might be wondering what theranostics means. Well, it’s a combination of two words: therapy and diagnostics. This is a type of medical treatment that involves both diagnosing and treating a disease […]
FDA approves new indication for Illuccix in metastatic prostate cancer
The PSMA-PET imaging product is now approved for the selection of patients with metastatic prostate cancer for whom 177Lu-PSMA-617 is indicated. Story: https://www.urologytimes.com/view/fda-approves-new-indication-for-illuccix-in-metastatic-prostate-cancer The FDA has approved a supplemental New Drug Application (sNDA) for Illuccix, a radiopharmaceutical cold kit for the preparation of gallium-68 (68Ga) gozetotide (PSMA-11) injection. The PSMA-PET imaging product is now approved […]
PET Scans: A High-Tech Look Inside Your Body
PET scans can still be very helpful for both you and your doctor. If you have any questions or concerns about PET scans, or if you’re thinking about having one, it’s always a good idea to talk to your doctor. They can give you more information and help you make a decision about whether a PET scan is the right choice for you.
PET Scan vs. CT Scan: What’s the Difference?
Both PET scans and CT scans are useful methods for diagnosing medical conditions. PET scans are particularly helpful for identifying and diagnosing cancer as well as other conditions like heart disease and brain disorders because they have the unique advantage of being able to provide functional information about the body’s tissues and organs. PET scans are an important tool in the field of medical imaging, despite having some drawbacks and perhaps not being as widely or inexpensively available as CT scans.